Effects of simvastatin administration in an experimental model of cancer cachexia.

[1]  R. Bellantone,et al.  Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. , 2002, Cytokine.

[2]  L. Andĕra,et al.  Coenzyme Q blocks biochemical but not receptor‐mediated apoptosis by increasing mitochondrial antioxidant protection , 2001, FEBS letters.

[3]  J. Soria,et al.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.

[4]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[5]  W. Sessa.  Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? , 2001, Trends in molecular medicine.

[6]  J. Egido,et al.  Transcription factor-kappa B (NF-kappa B) and renal disease. , 2001, Kidney international.

[7]  O. Grip,et al.  Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. , 2000, European journal of pharmacology.

[8]  H Sinzinger,et al.  Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. , 2000, Atherosclerosis.

[9]  T. Lee,et al.  Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. , 2000, The American journal of cardiology.

[10]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[11]  P. Kiener,et al.  Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. , 2000, Atherosclerosis.

[12]  P. Costelli,et al.  Cancer cachexia: from experimental models to patient management. , 2000, Current opinion in clinical nutrition and metabolic care.

[13]  K. Ichihara,et al.  Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. , 2000, Journal of cardiovascular pharmacology.

[14]  S. Harris,et al.  Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.

[15]  H. Kölsch,et al.  Induction of Apoptosis and Necrosis in Human Neuroblastoma Cells by Cholesterol Oxides , 1999, Annals of the New York Academy of Sciences.

[16]  R. Weiss,et al.  Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. , 1999, Journal of the American Society of Nephrology : JASN.

[17]  U. Ikeda,et al.  Statins and monocytes , 1999, The Lancet.

[18]  F. López‐Soriano,et al.  The role of cytokines in cancer cachexia , 1999, Medicinal research reviews.

[19]  H. Sinzinger,et al.  Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. , 1999, Atherosclerosis.

[20]  R. Rosenson,et al.  Inhibition of proinflammatory cytokine production by pravastatin , 1999, The Lancet.

[21]  R. Itti,et al.  Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. , 1999, Journal of cardiovascular pharmacology.

[22]  G. López-Lluch,et al.  Role of plasma membrane coenzyme Q on the regulation of apoptosis , 1999, BioFactors.

[23]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[24]  S. Dimauro,et al.  Mitochondria in neuromuscular disorders. , 1998, Biochimica et biophysica acta.

[25]  R. Schwartz,et al.  Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α , 1998 .

[26]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[28]  F. Rossi Fanelli,et al.  Cracking the riddle of cancer anorexia. , 1996, Nutrition.

[29]  J. Reijneveld,et al.  Differential Effects of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors on the Development of Myopathy in Young Rats , 1996, Pediatric Research.

[30]  L. Stevenson,et al.  Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  K. Folkers,et al.  Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. , 1995, Biochimica et biophysica acta.

[32]  R. Laaksonen,et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.

[33]  T. Scherstén,et al.  Coenzymes Q9 and Q10 in skeletal and cardiac muscle in tumour-bearing exercising rats. , 1995, European journal of cancer.

[34]  L. Tessitore,et al.  The role of apoptosis in growing and stationary rat ascites hepatoma, Yoshida AH‐130 , 1993, The Journal of pathology.

[35]  L. Tessitore,et al.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.

[36]  L. Tessitore,et al.  Humoral mediation for cachexia in tumour-bearing rats. , 1993, British Journal of Cancer.

[37]  N. Bizzaro,et al.  Massive rhabdomyolysis and simvastatin. , 1992, Clinical chemistry.

[38]  M. Muscaritoli,et al.  Abnormal substrate metabolism and nutritional strategies in cancer management. , 1991, JPEN. Journal of parenteral and enteral nutrition.

[39]  M. Battino,et al.  Studies on the role of ubiquinone in the control of the mitochondrial respiratory chain. , 1990, Free radical research communications.

[40]  M. Quiñones,et al.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. , 1988, JAMA.

[41]  L. Tessitore,et al.  Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. , 1987, The Biochemical journal.

[42]  W. Dewys.  Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance , 1986 .

[43]  A. Richmond,et al.  Metabolic approaches to cancer cachexia. , 1982, Annual review of nutrition.